Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 110 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Follow-Up Questions
What is the price performance of ORXOY stock?
The current price of ORXOY is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Orexo AB?
Orexo AB belongs to Pharmaceuticals industry and the sector is Health Care
What is Orexo AB market cap?
Orexo AB's current market cap is $NaN
Is Orexo AB a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Orexo AB, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
